Simone Song
Fortune : - $ au 31/08/2026
Fortune : - $ au 31/08/2026
Ms. Simone Song is a Founder & Senior Partner at ORI Capital Ltd. She is on the Board of Directors at Orchard Therapeutics (Europe) Ltd., Kymab Group Ltd. and Kymab Ltd.
Ms. Song was previously employed as an Independent Non-Executive Director by Orchard Therapeutics Plc, an Independent Director by CG Oncology, Inc., and a Managing Director by Cowen, Inc. She also served on the board at Trisalus Life Sciences, Inc. (United States).
She received her undergraduate degree from Fudan University and a graduate degree from Claremont Graduate University.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CG ONCOLOGY, INC. -.--% | 05/06/2025 | 0 ( -.--% ) | - $ | 31/08/2026 |
| Sociétés | Poste | Début |
|---|---|---|
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital invests in companies located across the globe. The firm targets companies operating in the fields of biotech with a focus on diagnostics, drug delivery, and therapeutics. It participates in early-stage transactions. | Fondateur | 01/07/2015 |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops human monoclonal antibody drugs | Directeur/Membre du Conseil | - |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Directeur/Membre du Conseil | 22/12/2017 |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops human monoclonal antibody drugs | Directeur/Membre du Conseil | 20/01/2017 |
| Sociétés | Poste | Fin |
|---|---|---|
| CG ONCOLOGY, INC. | Directeur/Membre du Conseil | 22/11/2025 |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for treatment of liver and pancreatic tumors | Directeur/Membre du Conseil | 01/01/2023 |
| COWEN INC. | Corporate Officer/Principal | - |
| ORCHARD THERAPEUTICS PLC | Directeur/Membre du Conseil | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 10 |
|---|---|
Claremont Graduate University
Claremont Graduate University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Fudan University
Fudan University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cowen, Inc.
Cowen, Inc. Investment Banks/BrokersFinance Provides corporate & investment banking and financial services | Finance |
Kymab Ltd.
Kymab Ltd. Pharmaceuticals: MajorHealth Technology Discovers and develops human monoclonal antibody drugs | Health Technology |
TriSalus Operating Life Sciences, Inc.
TriSalus Operating Life Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutics for treatment of liver and pancreatic tumors | Health Technology |
CG Oncology, Inc.
CG Oncology, Inc. BiotechnologyHealth Technology Operates as a late-stage clinical biopharmaceutical company focused on developing and commercializing backbone bladder-sparing therapeutic | Health Technology |
Orchard Therapeutics (Europe) Ltd.
Orchard Therapeutics (Europe) Ltd. BiotechnologyHealth Technology Researches on transformative gene therapies | Health Technology |
ORI Capital Investment Advisory Hong Kong Ltd.
ORI Capital Investment Advisory Hong Kong Ltd. Investment ManagersFinance ORI Capital invests in companies located across the globe. The firm targets companies operating in the fields of biotech with a focus on diagnostics, drug delivery, and therapeutics. It participates in early-stage transactions. | Finance |
Orchard Therapeutics Plc
Orchard Therapeutics Plc BiotechnologyHealth Technology Engages in research and advancements of gene therapy to develop potential cures for genetic & other severe diseases | Health Technology |
Kymab Group Ltd.
Kymab Group Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops human monoclonal antibody drugs | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national